HBP Helix BioPharma Corp
- 0.210
- 0.0000.00%
Helix BioPharma Corp News
Helix BioPharma Corp. Advances Despite Filing Delay
Helix BioPharma Corp. Progresses Amid Delays
Canadian Investment Regulatory Organization Trade Resumption - HBP
Helix BioPharma Corp. Secures New Funding
Canadian Investment Regulatory Organization Trading Halt - HBP
Helix BioPharma Corp. Announces Fiscal 2024 First Quarter Results
Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2024 first quarter results for the period ending October 31, 2023.
Helix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Helix BioPharma Corp. Announces Closing of Private Placement of CAD $3 Million and Board Changes
Helix Biopharma Corp. Reports Voting Results
Helix Biopharma Corp. Announces Grant & Cancellation of Stock Options
Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development
Toronto, Ontario --News Direct-- Helix BioPharma Corp.Toronto, Ontario – TheNewswire – September 1, 2022 – Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutica
Helix Biopharma Corp. Announces Conclusion of Funding Agreement With Lind Global Macro Fund LP
Toronto, Ontario --News Direct-- Helix BioPharma Corp.Toronto, Ontario – TheNewswire – August 30, 2022 – Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical
Helix BioPharma Corp. Announces Scientific Collaboration with University Hospital Tuebingen
Toronto, Ontario --News Direct-- Helix BioPharma Corp.Toronto, Ontario – TheNewswire – August 9, 2022 – Helix BioPharma Corp. (TSX:HBP) (OTC:HBPCF) ("Helix" or the "Company"), a clinical-stage biophar
Helix BioPharma (TSE:HBP) Share Price Passes Above 50-Day Moving Average of $0.21
Helix BioPharma Corp. (TSE:HBP – Get Rating)'s share price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$0.21 and traded as hi
HELIX BIOPHARMA Corp. Announces Fiscal 2022 Third Quarter Results
Toronto, Ontario --News Direct-- Helix BioPharma Corp.(Toronto Hill, Ontario) – TheNewswire – June 14, 2022 - Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceu
Helix Biopharma Corp. Announces Closure of Early Warrant Exercise Incentive Program | Raises Aggregate $3.21 Million
Toronto, Ontario --News Direct-- Helix BioPharma Corp.(Richmond Hill, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company d
Insiders may be rethinking their CA$3.0m Helix BioPharma Corp. (TSE:HBP) investment now that the company has lost CA$5.0m in value
Insiders who bought CA$3.0m worth of Helix BioPharma Corp.'s (TSE:HBP) stock at an average buy price of CA$0.26 over the last year may be disappointed by the recent 15% decrease in the stock. Insiders
Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.
VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Compa
Helix Biopharma Corp. Closes Private Placement
RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm
Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members
RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of imm
